Saracatinib (AZD0530, AZD-0530) (CAS: 379231-04-6) is a small-molecule inhibitor of Src family kinases, developed by AstraZeneca for the treatment of various cancers, such as breast cancer and prostate cancer. These kinases play a critical role in tumor progression and metastasis.
Chemical name: 5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-N-[(1S)-1-(hydroxymethyl)propyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
Molecular formula: C20H23ClN4O2
Formula weight: 386.87 g/mol
CAS No: 379231-04-6
Top ten keywords from Google:
Synonyms:
Health benefits of this product: Saracatinib has shown potential in preclinical and clinical studies for the treatment of various cancers, such as breast cancer and prostate cancer. It works by inhibiting the activity of Src family kinases, which promote tumor progression and metastasis. By blocking these kinases, saracatinib can potentially reduce tumor growth and metastasis.
Potential effects: Saracatinib has shown promising anti-tumor activity in preclinical and clinical studies. In particular, it has demonstrated efficacy in reducing tumor growth and inducing remission in breast cancer and prostate cancer. It has also shown potential in combination with other anti-cancer agents, such as chemotherapy and radiation therapy. However, more research is needed to determine its full potential and efficacy in different types of cancers.
Product mechanism: Saracatinib inhibits the activity of Src family kinases, which are involved in the regulation of various cellular processes, including cell proliferation, migration, and survival. Overexpression or activation of these kinases is associated with various cancers, such as breast cancer and prostate cancer. As a kinase inhibitor, saracatinib binds to the ATP-binding site of these kinases, preventing their activation and downstream signaling pathways that promote cancer cell growth and metastasis. By inhibiting these kinases, saracatinib can block tumor progression and metastasis.
Safety: Saracatinib has been evaluated in several preclinical and clinical studies involving hundreds of patients with different types of cancers. Overall, it has been well-tolerated, with manageable side effects. The most common adverse events reported were fatigue, nausea, and diarrhea. More severe side effects, such as liver toxicity and cardiovascular events, were observed in some patients, but they were rare and usually resolved after dose adjustments or discontinuation.
Side effects: Common side effects of saracatinib include fatigue, nausea, and diarrhea. These symptoms are usually mild or moderate and can be managed with supportive care or dose modifications. Less common but more severe side effects may include liver toxicity and cardiovascular events, which may require prompt medical intervention. Patients should be monitored closely for these adverse events and receive appropriate medical intervention if necessary.
Dosing information: The recommended dose of saracatinib varies depending on the indication and the patient's condition. In clinical trials, doses ranging from 50 to 175 mg/day have been evaluated, either as a single agent or in combination with other drugs. Treatment duration also varies and can range from a few weeks to several months, depending on the response and tolerability. Patients should follow their doctor's instructions regarding dosing, administration, and monitoring.
Conclusion: Saracatinib is a promising small-molecule inhibitor of Src family kinases that has shown potential in preclinical and clinical studies for the treatment of various cancers, such as breast cancer and prostate cancer. Its mechanism of action involves blocking key kinases involved in tumor progression and metastasis, leading to reduced tumor growth and metastasis. Although it has been generally well-tolerated, it may cause some side effects that should be monitored closely. Further research is needed to determine its full potential and efficacy in different types of cancers.
